Testing effectiveness (Phase 2)UnknownNCT05386524What this trial is testingSintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBCWho this might be right forBreast Cancer Fudan University 41
Testing effectiveness (Phase 2)Study completedNCT01653561What this trial is testingApatinib in Non-triple-negative Metastatic Breast CancerWho this might be right forBreast Neoplasms Fudan University 20
Testing effectiveness (Phase 2)Looking for participantsNCT06793332What this trial is testingBrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADCWho this might be right forTriple-Negative Breast Cancer (TNBC)Brain Metastases Fudan University 39
Early research (Phase 1)Ended earlyNCT06351332What this trial is testingZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBCWho this might be right forBreast CancerBreast Cancer FemaleTriple Negative Breast Cancer+2 more Filipa Lynce, MD 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT03090165What this trial is testingRibociclib and Bicalutamide in AR+ TNBCWho this might be right forTriple Negative Breast Cancer Kari Wisinski 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT06618014What this trial is testingNeoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)Who this might be right forBreast CancerTriple Negative Breast Cancer Sun Yat-sen University 51
Not applicableStudy completedNCT03465670What this trial is testingPeriodontal Wound Healing With CHX and Hyaluronic AcidWho this might be right forSurgical FlapsWound HealingGingiva University Hospital of Ferrara 37
Large-scale testing (Phase 3)Study completedNCT02164513What this trial is testingA Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)Who this might be right forPulmonary Disease, Chronic Obstructive GlaxoSmithKline 10,355
Testing effectiveness (Phase 2)Study completedNCT02730130What this trial is testingStudy to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer PatientsWho this might be right forBreast CancerMetastatic Triple Negative Memorial Sloan Kettering Cancer Center 17
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07153965What this trial is testingSacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast CancerWho this might be right forTriple Negative Breast Cancer (TNBC)PD-L1 Positive Tianjin Medical University Cancer Institute and Hospital 47
Testing effectiveness (Phase 2)Looking for participantsNCT06611839What this trial is testingVenetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AMLWho this might be right forAMLIDH1 MutationTreatment Institute of Hematology & Blood Diseases Hospital, China 23
Large-scale testing (Phase 3)Looking for participantsNCT07546981What this trial is testingEfficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonistsWho this might be right forAsthma Chiesi Farmaceutici S.p.A. 554
Not applicableStudy completedNCT06504524What this trial is testingCompare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and USWho this might be right forMultiple Myeloma Pfizer 633
Early research (Phase 1)Study completedNCT01920061What this trial is testingPF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)Who this might be right forNeoplasm Pfizer 110
Testing effectiveness (Phase 2)Looking for participantsNCT04434040What this trial is testingAtezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)Who this might be right forBreast CancerTriple Negative Breast CancerResidual Cancer+1 more Dana-Farber Cancer Institute 40
Testing effectiveness (Phase 2)Study completedNCT03499899What this trial is testingEfficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast CancerWho this might be right forTriple-negative Breast Cancer Novartis Pharmaceuticals 88
Post-approval studies (Phase 4)Not Yet RecruitingNCT05843292What this trial is testingShort-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast CancerWho this might be right forTriple-negative Breast Cancer Shanghai Jiao Tong University School of Medicine 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07124884What this trial is testing5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced UnresectabWho this might be right forColorectal CarcinomaKRAS G12C MutationUnresectable Colorectal Cancer Federation Francophone de Cancerologie Digestive 300
Very early researchLooking for participantsNCT05341492What this trial is testingEGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast CancerWho this might be right forEGFR/ B7H3-positive Advanced Lung CancerEGFR/ B7H3-positive Advanced Triple-negative Breast Cancer Second Affiliated Hospital of Guangzhou Medical University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06407310What this trial is testingNeoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast CancerWho this might be right forTriple Negative Breast Cancer Tel Aviv Medical Center 25